Anixa Begins Higher Dose Phase in Ovarian Cancer CAR-T Trial

Anixa Biosciences, a biotech firm listed on NASDAQ, has initiated treatment for a fourth participant in its Phase 1 clinical trial for a new CAR-T cell therapy aimed at ovarian cancer. This follows the successful treatment of the initial group of patients. The trial, in collaboration with Moffitt Cancer Center, includes patients with recurrent or resistant ovarian cancer who have undergone at least two prior treatments. The innovative therapy, known as CER-T, targets the Follicle Stimulating Hormone Receptor (FSHR), which is present on ovarian cells and tumor vasculature, offering a more specific approach than standard CAR-T treatments.
The first patient in the second cohort received a dosage three times higher than the initial group, with no safety concerns reported thus far. Dr. Amit Kumar, Anixa's CEO, expressed optimism about the potential of their cell therapy in treating solid tumors, a challenge for traditional CAR-T therapies that have shown success in blood-related cancers. Dr. Robert Wenham, the trial's lead investigator, highlighted the specificity of the target and the direct intraperitoneal administration of T-cells, which could reduce side effects like cytokine release syndrome (CRS).
Anixa's therapeutic offerings also include a vaccine in development with the Cleveland Clinic to prevent triple negative breast cancer (TNBC) and ovarian cancer, focusing on immunizing against proteins unique to certain cancers. The company's strategy involves partnering with leading research institutions to explore and commercialize new technologies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!